Chronic Disease Markets for Sustained Released Injectables: The Trend toward Self-Administration
Tuesday, January 23, 2024
DUBLIN, Jan. 15, 2024 /PRNewswire/ -- The "Chronic Disease Markets for Sustained Released Injectables" report has been added to ResearchAndMarkets.com's offering.
https://mma.prnewswire.com/media/539438/Research_and_Markets_Logo.jpg
The report provides a comprehensive evaluation and analysis of the technology, products and participants providing the driving force behind this evolving segment of the healthcare sector.
The study is designed to provide drug company decision makers, drug delivery developers, device designers, healthcare marketers, and supply chain participants with a detailed understanding of the economics, technologies, disease segments, and commercial opportunities for chronic disease markets for sustained release injectables. Provider organization business managers, healthcare administrators and investors will also benefit from this study.
Evolving Engineered Solutions
Chronic conditions require drug administration over long periods of time, placing a greater emphasis on self-administration. With the shift away from caregiver interaction, drug safety and compliance/adherence become prominent concerns. These concerns, which are not new, are becoming magnified as the number of powerful new drugs reaching the market increases. For healthcare managers and public health officials, one way to address these issues is less frequent dosing. Using formulation technologies designed to modulate the effect of therapeutic substances, drug developers are creating formulations that exhibit extended-release profiles. These chemistries include polymers such as polyethylene glycol-complexed (PEGylated), which are used to product encapsulated and coated versions of new APIs.
The goal is to address the requirement for patient-dependent, and therefore compliance-sensitive, drug treatment protocols such as multiple dosing through controlled release formulations that provide the desired therapeutic effect with dosing of once-a-day or less.
What You Will Learn
-- What are the marketed sustained release injectable drug products, what
sustained release formulation technologies are used, and who markets
them?
-- What are the major factors driving sustained release injectable drug
demand?
-- What sustained release injectable drug candidates are in late-stage
clinical development and what is their potential impact?
-- How important are drug developer-formulation technologist relationships
in the sustained release market segment, and what are the key alliances
in the industry?
-- What are the essential formulation factors, delivery device selection
issues, related technology factors and market development issues for
sustained release injectable drug products?
-- In what therapeutic market segments do sustained release injectables
compete? What is their market share today? What will it be in 2028? What
is their expected growth rate?
-- What are the significant economic, technology, and regulatory factors
affecting the market for sustained release injectables?
Key Topics Covered:
Injectable Drug Market Dynamics
-- The Trend toward Self-Administration
-- Injectable Drug Formulation Technology
-- Innovation in Injectable Device Designs
-- Therapeutic Demand Drivers
-- Market Factors
-- Competitive Landscape
-- Risk Factors
-- Sustained Release - Branded Formulation Technologies
-- Biodegradable Polymers
-- Branded SR Formulation Technologies
-- Physical Process Control Methods
-- Sustained Release Injectables - Development Factors
-- Formulation Factors
-- Stability
-- Lyophilization
-- Packaging
-- Administration Factors
-- SR Injectables - Product
Analysis & Market Sector Forecasts
-- Addiction
-- Naltrexone
-- Diabetes
-- Exenatide
-- Infectious Disease
-- Interferon
-- Hormone Deficiency
-- Estradiol
-- Somatropin
-- Testosterone
-- Metabolic Diseases
-- Acromegaly
-- Neurology
-- Oncology
-- Leukemia
-- Lymphoma
-- Cytarabine
-- Prostate
-- Pain Management
-- Reproductive Health
-- Fertility
-- Endometriosis
Market Profiles
Companies Mentioned
-- Alkermes
-- Amylin
-- AntriaBio
-- Ascendis Pharma
-- AstraZeneca
-- Aurobundo
-- Avadel
-- Biomarin
-- Camurus
-- Critical Pharmaceuticals
-- DURECT
-- Eli Lilly
-- Enzon
-- Ipsen
-- Janssen
-- NanOlogy
-- Novartis
-- OctoPlus
-- Oakwood Laboratories/PharmaSophia
-- Pacira
-- PhaseBio Pharmaceuticals
-- Recipharm AB
-- Roche
-- Sanofi
-- Taiwan Liposome Company
-- Xbrane Bipharma
For more information about this report visit https://www.researchandmarkets.com/r/2y1810
About ResearchAndMarkets.com
ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Media Contact:
Research and Markets
Laura Wood, Senior Manager
press@researchandmarkets.com
For E.S.T Office Hours Call +1-917-300-0470
For U.S./CAN Toll Free Call +1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
Logo: https://mma.prnewswire.com/media/539438/Research_and_Markets_Logo.jpg
View original content:https://www.prnewswire.com/news-releases/chronic-disease-markets-for-sustained-released-injectables-the-trend-toward-self-administration-302034521.html
SOURCE Research and Markets
|
|
|
|
|
 |
Asetek - Mandatory Notification of Trade | Jan 22, 2026
|
|
Tomorrowland Brings the Magic to Shanghai for a Spectacular First Indoor Edition in China | Jan 22, 2026
|
|
Rent Manager Earned Best Real Estate Software Product Award and Multiple Review Badges from G2 Platform | Jan 22, 2026
|
|
BC.GAME to Host "Stay Untamed" Night During Abu Dhabi's Packed Web3 Summit Week | Jan 22, 2026
|
|
Auburn University's Applied Research Institute Expands Advanced Manufacturing Capabilities with CF3D Enterprise Cell | Jan 22, 2026
|
|
AMPERA ANNOUNCES LOCATION FOR GLOBAL HEADQUARTERS | Jan 22, 2026
|
|
Culture and tourism sectors thrive in Xiamen | Jan 22, 2026
|
|
California Divorce Mediation Center Unveils Modern Website Redesign | Jan 22, 2026
|
|
AMPLIFY Named Finalist in Three Categories at the 2026 Golden Gavel Awards | Jan 22, 2026
|
|
Gemmy Alerts Customers: Fake Websites Target Holiday Decorators | Jan 22, 2026
|
|
|
